Dendritic Cell News and Research

Latest Dendritic Cell News and Research

Results of Argos' Arcelis Phase 2 study for RCC accepted for presentation at International Kidney Cancer Symposium

Argos Therapeutics today announced that results from its Arcelis™ immunotherapy Phase 2 study for the treatment of renal cell carcinoma (RCC) have been accepted for a poster presentation at the Ninth International Kidney Cancer Symposium on Oct. 1-2 in Chicago.

24 Sep 2010

Cytheris commences enrollment in CYT107 recombinant human Interleukin-7 clinical trial for HIV

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has begun enrolling patients in INSPIRE 3, a Phase II clinical program evaluating the effect of repeated cycles of the company's investigative immune-modulator, recombinant human Interleukin-7 (CYT107), in the treatment of chronically HIV-1 infected patients classified as Immunological Non-Responders (INR) after at least 24 months of highly active anti-retroviral therapy (HAART).

21 Sep 2010

Researchers identify protein essential for dendritic cell development

A protein called PU.1 is essential for the development of dendritic cells, the sentinels of the immune system, Walter and Eliza Hall Institute researchers in Melbourne, Australia, have shown.

20 Sep 2010

ImmunoCellular contracts with Averionto to execution ICT-107 cancer-vaccine Phase II study

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, today announced that it has contracted with the clinical research organization (CRO) Averion International Corp. to conduct its planned Phase II study of ICT-107, the Company's lead cancer-vaccine candidate for the treatment of glioblastoma multiforme (GBM).

17 Sep 2010

Scientists discover sensor in dendritic cells that recognizes HIV

Dendritic cells are the grand sentinels of the immune system, standing guard 24/7 to detect foreign invaders such as viruses and bacteria, and bring news of the invasion to other immune cells to marshal an attack. These sentinels, however, nearly always fail to respond adequately to HIV, the virus causing AIDS. Now a team of scientists at NYU Langone Medical Center has discovered a sensor in dendritic cells that recognizes HIV, spurring a more potent immune response by the sentinels to the virus.

9 Sep 2010

Zebrafish DCs discovery provide researchers to investigate mammalian immune system

Scientists from the University of California, San Diego School of Medicine have identified dendritic antigen presenting cells in zebrafish, opening the possibility that the tiny fish could become a new model for studying the complexities of the human immune system.

9 Sep 2010

ImmunoCellular Therapeutics announces long-term data from ICT-107 Phase I clinical trial for GBM

ImmunoCellular Therapeutics, a biotechnology company focused on the development of novel immune-based cancer therapies, today announced long-term data from a Phase I clinical trial of ICT-107, the Company's lead cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.

9 Sep 2010

ImmuneRegen's Homspera with Scancell's ImmunoBody technology improves immune response for cancer

ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. today announced that treatment with its lead compound, Homspera, in combination with a DNA vaccine utilizing Scancell's ImmunoBody technology significantly improved the immune response of the vaccine in an animal model.

8 Sep 2010

Positive immune responses elicited from Scancell's DNA vaccine in combination with ImmuneRegen's Homspera

Scancell Holdings Plc, the developer of therapeutic cancer vaccines, announces that a treatment utilising a DNA vaccine based on its ImmunoBody® technology, in combination with ImmuneRegen BioSciences, Inc.®'s lead compound, Homspera®, has significantly improved the immune response of the vaccine in an animal model. Follow-up studies are currently being performed to optimize the effects of Homspera in enhancing the next generation of Scancell's cancer vaccines.

7 Sep 2010

ImmunoCellular Therapeutics updates accomplishments in Letter to Shareholders

As the summer comes to a close, I wanted to update you on the Company's accomplishments this year, which set the stage for an exciting fall. The first eight months of the year have been very successful, with the Company attaining many of its goals, despite a very difficult economic environment, which has created challenges for many small biotechnology companies. Today, IMUC is in its best financial position ever and well positioned to validate the success it achieved in a Phase I trial for ICT-107, its dendritic cell-based cancer vaccine product candidate.

3 Sep 2010

Boryung Pharmaceutical implements Cegedim Dendrite's Mobile Intelligence CRM solution

Cegedim Dendrite, the world's leading provider of Life Sciences-specific customer relationship management (CRM) solutions, announced today that Boryung Pharmaceutical Co., Ltd., has implemented Cegedim Dendrite's Mobile Intelligence™ CRM solution. Boryung Pharmaceutical is one of Korea's top 10 domestic pharmaceutical companies, and Cegedim Dendrite currently serves 14 of the industry's top-grossing companies in Korea.

24 Aug 2010

ImmunoCellular Therapeutics raises $6.5 million in second quarter 2010

ImmunoCellular Therapeutics today announced second quarter results for the period ended June 30, 2010. The Company utilized $1.13 million of cash in its operations during the quarter. The increase in net burn is reflective of increased personnel costs as well as increase in Research and Development costs associated with the planned phase II clinical trial for ICT-107.

18 Aug 2010

Single neurons in brain distinguish different temporal sequences of incoming information

Single neurons in the brain are surprisingly good at distinguishing different sequences of incoming information according to new research by UCL neuroscientists.The study, published today in Science and carried out by researchers based at the Wolfson Institute for Biomedical Research at UCL, shows that single neurons, and indeed even single dendrites, the tiny receiving elements of neurons, can very effectively distinguish between different temporal sequences of incoming information.

13 Aug 2010

Cegedim Dendrite, TAKE Solutions form strategic partnership

As part of the Cegedim Dendrite Alliance Program, created to expand its open business model through alliances with leading technology, software and consulting companies, Cegedim Dendrite today announced its partnership in India with TAKE Solutions Ltd.

10 Aug 2010

Cegedim Dendrite, Capgemini to offer software solutions for Life Sciences companies

Cegedim Dendrite, the world's leading provider of pharmaceutical-specific Customer Relationship Management solutions, and Capgemini U.S. LLC ("Capgemini"), one of the world's foremost providers of consulting, technology and outsourcing services, announced an alliance to jointly offer software solutions, consulting and technology services around aggregate spend and customer master data to Life Sciences companies. Through the alliance, Capgemini will provide broad based consulting and implementation services associated with Cegedim Dendrite's AggregateSpend360™ and Nucleus 360™ solutions to pharmaceutical, biotech and medical device companies.

9 Aug 2010

Arcelis immunotherapy effective in treating autoimmune diseases: Study

Argos Therapeutics today announced that its Arcelis immunotherapy targeted at diabetes demonstrated potential for preventing and treating the disease in non-obese diabetic (NOD) mice, according to a peer-reviewed article published in Molecular Therapy.

4 Aug 2010

NWBT reports long-term follow-up data from DCVax-Brain immune therapy clinical trials for GBM

Northwest Biotherapeutics, Inc. today announced further positive long-term follow-up data from its prior Phase I and Phase I/II clinical trials, in which patients with newly diagnosed Glioblastoma multiforme ("GBM"), the most rapid and lethal type of brain cancer, were treated with NWBT's DCVax®-Brain personalized immune therapy.

3 Aug 2010

Major breakthrough in Alzheimer's disease research

Researchers from the University of Sydney's Alzheimer's and Parkinson's Disease Laboratory have achieved a major breakthrough by finding the causes of Alzheimer's disease at a cellular level and thereby identifying a potential therapy as a result.

23 Jul 2010

Argos' Arcelis immunotherapy reduces viral load in interim analysis of Phase 2 HIV trial

Argos Therapeutics today announced that, in an interim analysis of a Phase 2 trial, its Arcelis immunotherapy targeted at HIV, AGS-004, demonstrated a significant reduction in viral load and a delay in viral rebound kinetics during a 12-week antiretroviral treatment interruption (ARTI) when compared to pre-ART viral loads.

20 Jul 2010

Phase II data on Genetic Immunity's DermaVir vaccine to be presented at XVIII International AIDS Conference

Genetic Immunity, a US/Hungarian biopharmaceutical company developing nanomedicine-based immunotherapies for HIV/AIDS and other chronic diseases, is releasing Phase II data on the Company's novel DermaVir therapeutic vaccine for HIV/AIDS during the XVIII International AIDS Conference this week in Vienna, Austria. DermaVir, the first dendritic cell-targeting topical HIV vaccine candidate, employs nanotechnology to induce multi-faceted and long-lived immune responses capable of eliminating HIV infected cells.

19 Jul 2010

Dendritic Cell News and Research

Latest Dendritic Cell News and Research

Results of Argos' Arcelis Phase 2 study for RCC accepted for presentation at International Kidney Cancer Symposium

Cytheris commences enrollment in CYT107 recombinant human Interleukin-7 clinical trial for HIV

Researchers identify protein essential for dendritic cell development

ImmunoCellular contracts with Averionto to execution ICT-107 cancer-vaccine Phase II study

Scientists discover sensor in dendritic cells that recognizes HIV

Zebrafish DCs discovery provide researchers to investigate mammalian immune system

ImmunoCellular Therapeutics announces long-term data from ICT-107 Phase I clinical trial for GBM

ImmuneRegen's Homspera with Scancell's ImmunoBody technology improves immune response for cancer

Positive immune responses elicited from Scancell's DNA vaccine in combination with ImmuneRegen's Homspera

ImmunoCellular Therapeutics updates accomplishments in Letter to Shareholders

Boryung Pharmaceutical implements Cegedim Dendrite's Mobile Intelligence CRM solution

ImmunoCellular Therapeutics raises $6.5 million in second quarter 2010

Single neurons in brain distinguish different temporal sequences of incoming information

Cegedim Dendrite, TAKE Solutions form strategic partnership

Cegedim Dendrite, Capgemini to offer software solutions for Life Sciences companies

Arcelis immunotherapy effective in treating autoimmune diseases: Study

NWBT reports long-term follow-up data from DCVax-Brain immune therapy clinical trials for GBM

Major breakthrough in Alzheimer's disease research

Argos' Arcelis immunotherapy reduces viral load in interim analysis of Phase 2 HIV trial

Phase II data on Genetic Immunity's DermaVir vaccine to be presented at XVIII International AIDS Conference

Immunology eBook

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Dendritic Cell News and Research

Latest Dendritic Cell News and Research

Immunology eBook

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in